Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately.
"Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's pipeline and vision. I am excited by the benefit the company will gain with Miranda as part of our leadership team. Her strategic experience is a perfect fit, as we progress through our global partnership discussions and development of our proprietary oral delivery platform."
"I am excited to join Entera's management team at this critical juncture in the company's history, as our lead program EB613 prepares to fulfill its potential as the first oral anabolic for the treatment of post-menopausal women at high risk of osteoporosis," commented Miranda Toledano. "EB613 has shown compelling efficacy and safety and there is a clear unmet need for an oral agent to expand the PTH therapeutic class, which is well validated for close to 20 years. Further, Entera will continue to work with strategic partners to broaden our technology to additional high unmet need therapeutic categories, where oral delivery of large molecules is warranted."
Ms. Toledano most recently served as Chief Operating Officer, Chief Financial Officer and Director of TRIGR Therapeutics, an oncology focused, clinical stage bispecific antibody company acquired by Compass Therapeutics (NASDAQ:CMPX) in June 2021. At TRIGR, Miranda oversaw the clinical development and led strategic execution, including a $117 million China License Transaction and acquisition by CMPX. Previously, Ms. Toledano served as Head of Healthcare Investment Banking at MLV & Co. (acquired by B. Riley FBR & Co.), where she completed biotech equity financings (IPOs, ATMs, and follow-ons) totaling over $4 billion in aggregate value. Earlier in her career, Ms. Toledano served as vice president in the investment group of Royalty Pharma. Ms. Toledano currently serves as a member of our board of directors as well as a member of the board of directors of Compass Therapeutics (NASDAQ:CMPX), Journey Medical (NASDAQ:DERM) and NEXGEL (NASDAQ:NXGL). Ms. Toledano holds a B.A. in Economics from Tufts University and an MBA in Finance and Entrepreneurship from the NYU Stern School of Business.
About Entera Bio